FIA
SRPT icon

FNY Investment Advisers’s Sarepta Therapeutics SRPT Stock Holding History

FNY Investment Advisers’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-10
Closed -$1K – 938
2018
Q4 		$1K Hold
10
– – ﹤0.01% 633
2018
Q3 		$1K Sell
10
-8
-44% -$1.09K ﹤0.01% 819
2018
Q2 		$2K Buy
+18
New +$1.7K ﹤0.01% 841

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

FNY Investment Advisers's SRPT Position: Q4 2025 in Review

FNY Investment Advisers sold out of Sarepta Therapeutics (SRPT) in Q4 2025, closing a stake of 14 shares.

FNY Investment Advisers first reported a position in SRPT in Q2 2018 and held it in 9 quarters. The position peaked at $574K in Q2 2019. 346 funds tracked by Wall St. Rank hold SRPT as of Q4 2025.

  • FNY Investment Advisers reported no remaining Sarepta Therapeutics position as of Q4 2025 after selling out during the quarter.
  • FNY Investment Advisers sold 14 Sarepta Therapeutics shares in Q4 2025.
  • FNY Investment Advisers first reported a position in Sarepta Therapeutics in Q2 2018 and held it in 9 quarters.
  • FNY Investment Advisers's Sarepta Therapeutics position peaked at $574K in Q2 2019.
  • 346 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2025.

Based on FNY Investment Advisers's 13F filing for Q4 2025, filed 16 Jan 2026.